cagrisema cagrilintide semaglutide phase 3 results 2024 2025 Incretin-based therapies for the treatment of obesity-related diseases Dual Therapy CagriSema Promising for

But maximum dose comparison does not tell the whole story

RetatrutideMounjaro (Tirzepatide)Wegovy (Semaglutide) Mechanism Triple (GLP-1 + GIP + Glucagon)Dual (GLP-1 + GIP)Single (GLP-1) Best weight loss in trials 30.3%22.5%20.7% Trial duration 104 weeks72 weeks72 weeks UK approval Not yetYes (Mounjaro)Yes (Wegovy) Injection frequency Once weeklyOnce weeklyOnce weekly One important caveat: the 30.3% figure comes from a 104-week trial, while the Mounjaro and Wegovy results are from 72-week trials

: Forget messy powders and artificial mixes, these green tea extract capsules deliver fast, effective absorption in easy-to-take powerful capsules

L., Shannon, J., Frei, B., Kaye, J

Other Human Trials & Competitive Strategies Outside the BELIEVE trial, other clinical programs have tested ways to protect muscle during weight reduction